Background: Nivolumab (Opdivo, Bristol-Myers Squibb) is a human IgG4 monoclonal antibody with high affinity for the programmed death-1 receptor and is the first programmed death-1 immune checkpoint inhibitor approved by the U.S. Food and Drug Administration for second-line treatment of patients with advanced squamous and nonsquamous non–small cell lung cancer (1). Because of its “unbalancing” effect on the immune system, nivolumab may trigger immune-related adverse events (IRAEs), especially among patients with an autoimmune predisposition (2).
Objective: To present a case of nivolumab-induced recurrence of rheumatoid arthritis successfully treated with concurrent administration of prednisolone in a patient with advanced non–small cell ...
References
- 1.
Guibert N ,Mazières J . Nivolumab for treating non-small cell lung cancer. Expert Opin Biol Ther. 2015;15:1789-97. [PMID:26574148 ] doi:10.1517/14712598.2015.1114097 CrossrefMedlineGoogle Scholar - 2.
Michot JM ,Bigenwald C ,Champiat S ,Collins M ,Carbonnel F ,Postel-Vinay S ,et al . Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48. [PMID:26765102 ] doi:10.1016/j.ejca.2015.11.016 CrossrefMedlineGoogle Scholar - 3.
Teply BA ,Lipson EJ . Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park). 2014;28 Suppl 3:30-8. [PMID:25384885 ] MedlineGoogle Scholar - 4.
Narita T ,Oiso N ,Taketomo Y ,Okahashi K ,Yamauchi K ,Sato M ,et al . Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol. 2016;43:210-4. [PMID:26198822 ] doi:10.1111/1346-8138.13028 CrossrefMedlineGoogle Scholar - 5.
Kong BY ,Micklethwaite KP ,Swaminathan S ,Kefford RF ,Carlino MS . Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016;26:202-4. [PMID:26795275 ] doi:10.1097/CMR.0000000000000232 CrossrefMedlineGoogle Scholar
Author, Article and Disclosure Information
From “Sotiria” Athens General Hospital, University of Athens School of Medicine, Athens, Greece.
Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0137.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.